Company intelligence / Profile preview

Luxia Scientific

Paris, Ile de France, France6sense.com ↗

Ownership: Private
Development stage: Commercial

Overview

Luxia Scientific offers a commercial gut microbiome test called "1test1™" which was launched in France in October 2018 and Luxembourg in November 2018. The test costs 288€ and provides analysis of intestinal microbiota.

Therapeutic areas: OtherChronic Diseases
Modalities: Microbiome diagnostics
Industry: Molecular Diagnostics

Partnerships

IBBL (Integrated BioBank of Luxembourg)INRAMetaGenoPolis

Beyond the preview

Go deeper on Luxia Scientific.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Luxia Scientific.

Explore the full profile